vs
Side-by-side financial comparison of Six Flags Entertainment Corporation (FUN) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($311.4M vs $225.6M, roughly 1.4× Six Flags Entertainment Corporation). Bio-Techne runs the higher net margin — 16.4% vs -119.0%, a 135.4% gap on every dollar of revenue. On growth, Six Flags Entertainment Corporation posted the faster year-over-year revenue change (11.7% vs -1.5%).
Six Flags, officially Six Flags Entertainment Corporation, is an American amusement park company headquartered in Charlotte, North Carolina, United States. The company has 42 locations in its portfolio, including 27 amusement parks and 15 water parks, with nine on-site resort properties. Formed on July 1, 2024, following a merger of equals between longtime competitors Cedar Fair and the former Six Flags company, it is the largest regional amusement park operator in the world. Upon completion ...
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
FUN vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $225.6M | $311.4M |
| Net Profit | $-268.6M | $51.0M |
| Gross Margin | — | 66.9% |
| Operating Margin | — | 24.2% |
| Net Margin | -119.0% | 16.4% |
| Revenue YoY | 11.7% | -1.5% |
| Net Profit YoY | -22.2% | 126.0% |
| EPS (diluted) | — | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $225.6M | $311.4M | ||
| Q4 25 | $650.1M | $295.9M | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $930.4M | $317.0M | ||
| Q1 25 | $202.1M | $316.2M | ||
| Q4 24 | — | $297.0M | ||
| Q3 24 | $1.3B | $289.5M | ||
| Q2 24 | $571.6M | $306.1M |
| Q1 26 | $-268.6M | $51.0M | ||
| Q4 25 | $-92.4M | $38.0M | ||
| Q3 25 | $-1.2B | — | ||
| Q2 25 | $-99.6M | $-17.7M | ||
| Q1 25 | $-219.7M | $22.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | $111.0M | $33.6M | ||
| Q2 24 | $55.6M | $40.6M |
| Q1 26 | — | 66.9% | ||
| Q4 25 | 91.4% | 64.6% | ||
| Q3 25 | 91.6% | — | ||
| Q2 25 | 91.3% | 62.7% | ||
| Q1 25 | 89.3% | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | 91.9% | 63.2% | ||
| Q2 24 | 90.7% | 66.4% |
| Q1 26 | — | 24.2% | ||
| Q4 25 | -3.8% | 18.4% | ||
| Q3 25 | -83.7% | — | ||
| Q2 25 | 8.0% | -7.5% | ||
| Q1 25 | -158.9% | 12.2% | ||
| Q4 24 | — | 16.0% | ||
| Q3 24 | 19.5% | 13.8% | ||
| Q2 24 | 21.6% | 15.0% |
| Q1 26 | -119.0% | 16.4% | ||
| Q4 25 | -14.2% | 12.8% | ||
| Q3 25 | -90.1% | — | ||
| Q2 25 | -10.7% | -5.6% | ||
| Q1 25 | -108.7% | 7.1% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | 8.2% | 11.6% | ||
| Q2 24 | 9.7% | 13.3% |
| Q1 26 | — | $0.32 | ||
| Q4 25 | $-0.93 | $0.24 | ||
| Q3 25 | $-11.77 | — | ||
| Q2 25 | $-0.99 | $-0.11 | ||
| Q1 25 | $-2.20 | $0.14 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | $1.10 | $0.21 | ||
| Q2 24 | — | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $116.5M | $209.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $279.2M | $2.1B |
| Total Assets | $7.7B | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $116.5M | $209.8M | ||
| Q4 25 | $91.1M | $172.9M | ||
| Q3 25 | $70.7M | — | ||
| Q2 25 | $107.4M | $162.2M | ||
| Q1 25 | $61.5M | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | $89.7M | $187.5M | ||
| Q2 24 | $52.9M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | $5.2B | $260.0M | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $5.3B | $346.0M | ||
| Q1 25 | $5.0B | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | $4.6B | $300.0M | ||
| Q2 24 | $2.3B | $319.0M |
| Q1 26 | $279.2M | $2.1B | ||
| Q4 25 | $549.8M | $2.0B | ||
| Q3 25 | $614.3M | — | ||
| Q2 25 | $1.8B | $1.9B | ||
| Q1 25 | $1.8B | $2.0B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | $2.3B | $2.1B | ||
| Q2 24 | — | $2.1B |
| Q1 26 | $7.7B | $2.6B | ||
| Q4 25 | $7.8B | $2.5B | ||
| Q3 25 | $7.9B | — | ||
| Q2 25 | $9.5B | $2.6B | ||
| Q1 25 | $9.2B | $2.6B | ||
| Q4 24 | — | $2.7B | ||
| Q3 24 | $9.4B | $2.7B | ||
| Q2 24 | $2.3B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 9.40× | 0.13× | ||
| Q3 25 | 8.16× | — | ||
| Q2 25 | 2.97× | 0.18× | ||
| Q1 25 | 2.75× | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | 1.95× | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FUN
| In-park admissions revenues | $113.4M | 50% |
| In-park product revenues | $89.0M | 39% |
| Out-of-park revenues | $28.8M | 13% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
